 | |
| Clinical data | |
|---|---|
| Other names | 2,5-Dimethoxy-3,4-(tetramethylene)phenethylamine; 3,4-Tetramethylene-2,5-dimethoxyphenethylamine; 6-(2-Aminoethyl)-5,8-dimethoxytetralin |
| Routes of administration | Unknown[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Onset of action | Unknown[1] |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C14H21NO2 |
| Molar mass | 235.327 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
2C-G-4, also known as2,5-dimethoxy-3,4-(tetramethylene)phenethylamine or as6-(2-aminoethyl)-5,8-dimethoxytetralin, is achemical compound of thephenethylamine and2C families.[1] It is thederivative of2C-G (2C-G-0) in which the 3,4-dimethyl groups have been connected via two additionalcarbonatoms to form acyclohexanering attached to thebenzene ring and hence has atetralin (1,2,3,4-tetrahydronaphthalene)ring system.[1] The compound was included byAlexander Shulgin as an entry in his 1991 bookPiHKAL (Phenethylamines I Have Known and Loved).[1] However, Shulgin was unable to complete the last step of thechemical synthesis of the compound and never tested it.[1] In any case, he anticipated that it would be an active compound.[1] The synthesis of 2C-G-4 has been described.[1] 2C-G-4 was first described in the literature by Shulgin inPiHKAL in 1991.[1]
 | Thishallucinogen-related article is astub. You can help Wikipedia byexpanding it. |
